Efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for palmoplantar psoriasis in patients with moderate to severe plaque psoriasis in phase 2 and phase 3 (ESTEEM) trials - 09/05/15
Robert Bissonnette, MD, Universite de Montreal, Montreal, Quebec, Canada; Jennifer Cather, MD, Modern Research Associates, Dallas, TX, United States; Phoebe Rich, MD, Oregon Health Sciences University, Portland, OR, United States; Alan Menter, MD, Baylor University Medical Center, Dallas, TX, United States; Carlos Ferrandiz, MD, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; Mark Goodfield, MD, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, United Kingdom; ChiaChi Hu, MS, Celgene Corporation, Warren, NJ, United States; Robert Day, PhD, Celgene Corporation, Warren, NJ, United States; Michael Sebastian, MD, Gemeinschaftspraxis Mahlow, Mahlow, Germany
Le texte complet de cet article est disponible en PDF. 100% is Sponsored by Celgene Corporation. |
Vol 72 - N° 5S1
P. AB234 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?